Radiology & Cancer Research

Objective: This study aimed to evaluate the efficacy of stereotactic radiosurgery (SRS) combined with bevacizumab (BEV) compared with stereotactic radiosurgery and temozolomide (TMZ) for recurrent high-grade gliomas (HGGs). Methods: Patients with recurrent high-grade glioma who received SRS+BEV (n=35) or SRS+TMZ (n=23) between June 2013 and September 2017 were retrospectively analyzed. All patients were diagnosed with high-grade glioma by operation or biopsy. They received conventional radiotherapy (total about 60Gy) before this treatment. SRS was administered at a median dose of 14Gy, which was followed by BEV administration intravenously at 5mg/Kg with an interval of 1 month. Results: The median overall survival (OS) in the SRS+BEV group was significantly longer than that in the SRS+TMZ group (11.4 vs. 6.2 months; p=0.02). In patients with isocitrate dehydrogenase (IDH) wild-type tumors, the SRS+BEV treatment significantly prolonged survival than the SRS+TMZ treatment (10.7 vs. 5.7 months; p=0.01). One-year survival and two-year survival in the SRS+BEV group were 65.7% and 28.6% respectively, significantly higher than the SRS+TMZ group (51.9% and 18.5%). No severe adverse effect was found. Conclusion: SRS+BEV significantly prolonged survival duration than SRS+TMZ and improve the life quality in patients with recurrent high-grade glioma.